Literature DB >> 23295873

Phenotypic and molecular characterization of antimicrobial resistance and virulence factors in Pseudomonas aeruginosa clinical isolates from Recife, State of Pernambuco, Brazil.

Paula Regina Luna de Araújo Jácome1, Lílian Rodrigues Alves, Adriane Borges Cabral, Ana Catarina Souza Lopes, Maria Amélia Vieira Maciel.   

Abstract

INTRODUCTION: The emergence of carbapenem resistance mechanisms in Pseudomonas aeruginosa has been outstanding due to the wide spectrum of antimicrobial degradation of these bacteria, reducing of therapeutic options.
METHODS: Sixty-one clinical strains of P. aeruginosa isolated from five public hospitals in Recife, Pernambuco, Brazil, were examined between 2006 and 2010, aiming of evaluating the profiles of virulence, resistance to antimicrobials, presence of metallo-β-lactamase (MBL) genes, and clonal relationship among isolates.
RESULTS: A high percentage of virulence factors (34.4% mucoid colonies; 70.5% pyocyanin; 93.4% gelatinase positives; and 72.1% hemolysin positive) and a high percentage of antimicrobial resistance rates (4.9% pan-resistant and 54.1% multi-drug resistant isolates) were observed. Among the 29 isolates resistant to imipenem and/or ceftazidime, 44.8% (13/29) were MBL producers by phenotypic evaluation, and of these, 46.2% (6/13) were positive for the blaSPM-1 gene. The blaIMP and blaVIM genes were not detected. The molecular typing revealed 21 molecular profiles of which seven were detected in distinct hospitals and periods. Among the six positive blaSPM-1 isolates, three presented the same clonal profile and were from the same hospital, whereas the other three presented different clonal profiles.
CONCLUSIONS: These results revealed that P. aeruginosa is able to accumulate different resistance and virulence factors, making the treatment of infections difficult. The identification of blaSPM-1 genes and the dissemination of clones in different hospitals, indicate the need for stricter application of infection control measures in hospitals in Recife, Brazil, aiming at reducing costs and damages caused by P. aeruginosa infections.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23295873     DOI: 10.1590/s0037-86822012000600010

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  5 in total

1.  Detection of Metallo-Beta Lactamases Among Carbapenem-Resistant Pseudomonas aeruginosa.

Authors:  Ahmad Farajzadeh Sheikh; Soodabeh Rostami; Abbas Jolodar; Mohammad Amin Tabatabaiefar; Farzin Khorvash; Azadeh Saki; Saeed Shoja; Raheleh Sheikhi
Journal:  Jundishapur J Microbiol       Date:  2014-11-01       Impact factor: 0.747

2.  Glutathione Enhances Antibiotic Efficiency and Effectiveness of DNase I in Disrupting Pseudomonas aeruginosa Biofilms While Also Inhibiting Pyocyanin Activity, Thus Facilitating Restoration of Cell Enzymatic Activity, Confluence and Viability.

Authors:  Theerthankar Das; Martin Simone; Amaye I Ibugo; Paul K Witting; Mike Manefield; Jim Manos
Journal:  Front Microbiol       Date:  2017-12-14       Impact factor: 5.640

3.  Virulence Factors Of Carbapenem-Resistant Pseudomonas aeruginosa In Hospital-Acquired Infections In Mansoura, Egypt.

Authors:  Rasha El-Mahdy; Ghada El-Kannishy
Journal:  Infect Drug Resist       Date:  2019-11-07       Impact factor: 4.003

4.  Detection of blaPER-1 & blaOxa10 among imipenem resistant isolates of Pseudomonas aeruginosa isolated from burn patients hospitalized in Shiraz Burn Hospital.

Authors:  Amir Emami; Abdollah Bazargani; Ali Akbar Mohammadi; Mitra Zardosht; Seyed Morteza Seyed Jafari
Journal:  Iran J Microbiol       Date:  2015-02

5.  Biofilm production by clinical isolates of Pseudomonas aeruginosa and structural changes in LasR protein of isolates non biofilm-producing.

Authors:  Jailton Lobo da Costa Lima; Lilian Rodrigues Alves; Paula Regina Luna de Araújo Jacomé; João Pacífico Bezerra Neto; Maria Amélia Vieira Maciel; Marcia Maria Camargo de Morais
Journal:  Braz J Infect Dis       Date:  2018-03-28       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.